Array Biopharma Inc  

(Public, NASDAQ:ARRY)   Watch this stock  
Find more results for ARRY
3.24
+0.07 (2.21%)
After Hours: 3.24 0.00 (0.00%)
Aug 26, 5:02PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.18 - 3.29
52 week 2.38 - 6.04
Open 3.19
Vol / Avg. 1.58M/1.92M
Mkt cap 461.14M
P/E     -
Div/yield     -
EPS -0.65
Shares 145.02M
Beta 1.99
Inst. own 90%
Nov 2, 2016
Q1 2017 Array Biopharma Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Oct 28, 2016
Array Biopharma Inc Annual Shareholders Meeting (Estimated) - 3:00PM EDT - Add to calendar
Sep 7, 2016
Array Biopharma Inc at Wells Fargo Securities Healthcare Conference - 9:55AM EDT - Add to calendar
Aug 4, 2016
Q4 2016 Array Biopharma Inc Earnings Release
Aug 4, 2016
Q4 2016 Array Biopharma Inc Earnings Call - Webcast
Jul 12, 2016
Array Biopharma Inc at Cantor Fitzgerald Healthcare Conference
Jun 9, 2016
Array Biopharma Inc at Jefferies Healthcare Conference
Jun 5, 2016
Array Biopharma Inc Cocktail Reception with Investors and Analysts
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2016
Net profit margin -57.90% -67.33%
Operating margin -51.63% -59.62%
EBITD margin - -59.62%
Return on average assets - -
Return on average equity - -
Employees 156 -
CDP Score - -

Address

3200 Walnut St
BOULDER, CO 80301-2514
United States - Map
+1-303-3816600 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer. The Company’s wholly owned clinical stage drugs include Filanesib in Phase II clinical trials, is indicated for Kinesin spindle protein (KSP), inhibitor for MM; ARRY-797 in Phase II clinical trials, indicated for p38 inhibitor for Lamin A/C-related dilated cardiomyopathy (LMNA-DCM); ARRY-502 in Phase II clinical trials, indicated for CRTh2 antagonist for asthma, and ARRY-614 in Phase I clinical trials, is indicated for p38/Tie2 dual inhibitor for myelodysplastic syndromes (MDS). In addition, the Company has 11 ongoing partner-funded clinical programs, including two MEK inhibitors, which are both in Phase III clinical trials, binimetinib with Novartis and selumetinib with AstraZeneca.

Officers and directors

Kyle Lefkoff Independent Chairman of the Board
Bio & Compensation  - Reuters
Ron Squarer Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Jason Haddock Chief Financial Officer
Bio & Compensation  - Reuters
Andrew R. Robbins Chief Operating Officer
Age: 39
Bio & Compensation  - Reuters
Nicholas A. Saccomano Ph.D. Chief Scientific Officer
Age: 56
Bio & Compensation  - Reuters
John R. Moore Vice President, General Counsel, Secretary
Age: 51
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Victor Sandor Chief Medical Officer
Age: 49
Bio & Compensation  - Reuters
Charles M. Baum M.D., Ph.D. Independent Director
Age: 57
Bio & Compensation  - Reuters
Gwendolyn A. Fyfe M.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
John A. Orwin Independent Director
Age: 51
Bio & Compensation  - Reuters